Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Mar;19(3):339-41.
doi: 10.5588/ijtld.14.0814.

Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment

M R Farhat  1 , C D Mitnick  2 , M F Franke  3 , D Kaur  4 , A Sloutsky  4 , M Murray  5 , K R Jacobson  6
Affiliations
Comparative Study

Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment

M R Farhat et al. Int J Tuberc Lung Dis. 2015 Mar.

Abstract

Fluoroquinolone (FQ) drug susceptibility testing (DST) is an important step in the design of effective treatment regimens for multidrug-resistant tuberculosis. Here we compare ciprofloxacin, ofloxacin and moxifloxacin (MFX) resistance results from 226 multidrug-resistant samples. The low level of concordance observed suggests that DST should be performed for the specific FQ planned for clinical use. The results also support the new World Health Organization recommendation for testing MFX at a critical concentration of 2.0 μg/ml.

PubMed Disclaimer

Figures

Figure 1
Figure 1
DST results. A- Venn diagram of a subset of the DST results showing overlap between ciprofloxacin (CIP), moxifloxacin (MOXI) and ofloxacin (OFLX) resistance (number outside the circle represents the number of isolates sensitive by testing for all three drugs). I or R designations are as defined in Table 1. B- Cross tabulation of MOXI and OFLX MIC results, all drug concentrations are in μg/ml. Numbers in the cells represent strain counts, total=226 strains.
See this image and copyright information in PMC

References

    1. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, et al. Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality. PLoS ONE. 2013 Mar 13;8(3):e58664. - PMC - PubMed
    1. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2012 May;67(5):1088–93. - PubMed
    1. Companion handbook: to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. [Internet] WHO Press; Geneva: 2014. [cited 2014 Sep 23]. Available from: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?.... - PubMed
    1. Böttger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2011 Aug;17(8):1128–34. - PubMed
    1. Horne DJ, Pinto LM, Arentz M, Lin S-YG, Desmond E, Flores LL, et al. Diagnostic Accuracy and Reproducibility of WHO-Endorsed Phenotypic Drug Susceptibility Testing Methods for First-Line and Second-Line Antituberculosis Drugs. J Clin Microbiol. 2013 Feb;51(2):393–401. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources